Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

DOJ Sends Warning In Gender Care Provider Subpoenas No Photo Available

Dan McKay

The announcement of federal subpoenas targeting doctors who offer gender-affirming care signals an escalation in the Trump administrat... (more story)

Courts Face Early Push To Expand Justices' Injunction Ruling No Photo Available

Katie Buehler

In the two weeks since the U.S. Supreme Court curtailed federal judges' ability to issue universal injunctions, Trump administration a... (more story)

Merck's $10B Pulmonary Power Play Is Among Its Top 5 Deals No Photo Available

Al Barbarino

When Merck agreed to purchase respiratory disease-focused Verona Pharma PLC for $10 billion, it became one of Merck's largest deals ev... (more story)